Philip Morris International
PM
$190.82
-0.61%
Philip Morris International Inc. (PM) is a global tobacco company that manufactures and sells cigarettes and reduced-risk products, including heated tobacco units (IQOS), nicotine pouches (ZYN), and vapes (Veev), primarily outside the United States. As a spin-off from Altria in 2008, PMI has established itself as a market leader in the transition to smoke-free alternatives, with IQOS and ZYN dominating their respective categories in many international markets. The current investor narrative centers on PMI's accelerating growth in reduced-risk products, which now account for a significant portion of revenue, and the company's ability to offset declining combustible volumes with premium smoke-free offerings. Recent attention has also focused on the company's strong pricing power, robust dividend yield, and the potential for continued margin expansion as the product mix shifts toward higher-margin alternatives.…
PM
Philip Morris International
$190.82
Related headlines
Investment Opinion: Should I buy PM Today?
Rating: Buy. PM is a high-quality defensive stock with a compelling growth story in reduced-risk products. The analyst consensus is 'Buy' with an average target of $203.80, implying a 6.8% upside. The thesis is supported by accelerating revenue growth (9.09% YoY), high margins (gross 67.1%, operating 36.7%), and a PEG of 0.36, which suggests undervaluation relative to growth.
Sign up to view all
PM 12-Month Price Forecast
The AI assessment is bullish on PM, driven by its strong growth in reduced-risk products, attractive valuation metrics, and robust cash flow. The company's ability to transition from combustibles to smoke-free alternatives is a key differentiator, and the current valuation does not fully reflect this growth potential. However, the medium confidence reflects the risks from regulatory actions and competition. If PM can sustain RRP growth above 10% and maintain margins, the stock could re-rate higher. Conversely, any regulatory setback or growth deceleration would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $203.80 and implied upside of +6.8% versus the current price.
Average Target
$203.80
0 analysts
Implied Upside
+6.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $225
Analyst target range
The target price range spans from a low of $175.00 to a high of $225.00, representing a wide spread of $50, which indicates significant uncertainty about PM's future performance. The high target of $225 implies a 17.9% upside and likely assumes continued strong growth in reduced-risk products, successful market expansion, and potential multiple expansion. The low target of $175 suggests a downside of 8.3% and may price in risks such as regulatory challenges, increased competition, or slower adoption of smoke-free alternatives. The wide range reflects the ongoing debate about the sustainability of PMI's transformation and the impact of regulatory pressures on the tobacco industry. Overall, the consensus leans bullish, but the spread highlights the need for investors to consider both the upside potential and the risks.
Bulls vs Bears: PM Investment Factors
PM presents a balanced investment case with strong fundamentals, including accelerating revenue growth, high margins, and attractive valuation metrics like a PEG of 0.36. However, the stock trades at a premium PE and faces structural declines in combustible volumes and regulatory risks. The bull case is currently stronger, supported by the successful transition to reduced-risk products and robust cash flow, but the bear case highlights the potential for multiple compression and regulatory shocks. The key tension is whether PM can sustain its RRP growth momentum to offset declining combustibles and justify its premium valuation. If RRP growth continues at 9%+ and margins hold, the stock could re-rate higher; if not, the premium could unwind.
Bullish
- Strong Revenue Growth Acceleration: Q1 2026 revenue grew 9.09% YoY to $10.146B, up from 8.9% growth in Q1 2025, indicating accelerating momentum. This is driven by reduced-risk products (RRPs) which generated $4.379B in revenue, now a significant portion of the mix.
- Attractive Valuation with PEG of 0.36: The PEG ratio of 0.36x suggests the stock is undervalued relative to its growth rate, as a PEG below 1 typically indicates undervaluation. This is supported by a forward PE of 20.81x, which is reasonable for a company with consistent earnings growth.
- High Gross and Operating Margins: Gross margin stands at 67.1% and operating margin at 36.7%, reflecting strong pricing power and operational efficiency. These margins are among the highest in the consumer staples sector, providing a buffer against cost inflation.
- Robust Free Cash Flow Generation: Free cash flow (TTM) is $10.666B, providing ample capacity for dividend payments and debt reduction. This supports the 3.46% dividend yield and a payout ratio of 76%, which is sustainable given the cash flow.
Bearish
- High Valuation Relative to Peers: PM trades at a trailing PE of 22.06x, which is at a premium to the broader market and its historical average. This leaves limited room for multiple expansion and increases vulnerability to earnings disappointments.
- Declining Combustible Volumes: While RRP revenue is growing, combustible products still contribute $5.767B in revenue, and volumes are declining due to health concerns and regulation. This creates a structural headwind that could offset RRP gains if not managed carefully.
- Regulatory and Litigation Risks: The tobacco industry faces stringent regulations, including potential bans on certain products and increased taxation. Any adverse regulatory developments could significantly impact PM's operations and profitability.
- High Payout Ratio Limits Growth Investments: The payout ratio of 76% leaves limited retained earnings for reinvestment in new product development or market expansion. This could slow the growth of RRPs if competition intensifies.
PM Technical Analysis
PM is currently in a strong uptrend, with the stock price at $190.82 as of July 31, 2026, reflecting a 16.32% gain over the past year. The stock is trading at 91.8% of its 52-week range (between $142.11 low and $207.76 high), indicating it is near the upper end of its yearly range, which typically signals positive momentum and investor confidence. The price has recovered significantly from its 52-week low, and the current level suggests that the market is rewarding the company's growth trajectory, though the proximity to the high could also imply limited short-term upside without a breakout.
Beta
0.41
0.41x market volatility
Max Drawdown
-21.3%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+16.3%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +7.4% | +0.3% |
| 3m | +14.7% | +4.0% |
| 6m | +6.3% | +8.3% |
| 1y | +16.3% | +20.2% |
| ytd | +19.0% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue growth has been robust, with the most recent quarter (Q1 2026) reporting revenue of $10.146 billion, a 9.09% year-over-year increase. This growth is driven by strong performance in reduced-risk products, which generated $4.379 billion in revenue, while combustible products contributed $5.767 billion. The company has consistently grown revenue over the past several quarters, with Q4 2025 revenue at $10.362 billion and Q3 2025 at $10.845 billion, indicating a stable upward trajectory. The growth is accelerating, as Q1 2026's YoY growth of 9.09% is higher than the previous year's Q1 growth of 8.9%, suggesting that the shift to smoke-free products is gaining traction.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Given that PM has positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 22.06x, while the forward PE is 20.81x, indicating that the market expects earnings growth of approximately 6% over the next year. This gap between trailing and forward PE suggests moderate growth expectations, which is reasonable given the company's consistent earnings performance. The PEG ratio of 0.36x further supports the view that the stock is attractively valued relative to its growth rate, as a PEG below 1 typically indicates undervaluation.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: PM carries a significant debt load, with a debt-to-equity ratio of -4.89 (negative due to buybacks), but interest expenses of $237M in Q1 2026 indicate substantial debt. The current ratio of 0.96 suggests potential liquidity concerns, though the company generates strong free cash flow of $10.7B TTM. The high payout ratio of 76% limits financial flexibility, and any earnings miss could strain dividend coverage. Revenue concentration in combustible products (56.8% of Q1 revenue) exposes PM to volume declines, though RRP growth is mitigating this risk.
FAQ
The key risks are: 1) Regulatory risk: Governments may impose stricter regulations on tobacco and nicotine products, which could limit sales. 2) Competitive risk: Increased competition from other tobacco companies and new entrants in the nicotine pouch market could erode market share. 3) Macro risk: Economic downturns could reduce consumer spending on premium products. 4) Company-specific risk: The transition to RRPs may not be as successful as expected, leading to slower growth. The most severe risk is a regulatory ban on flavored products, which could significantly impact ZYN sales.
The 12-month forecast for PM is positive, with a base case target of $195-$210 (50% probability), a bull case of $210-$225 (30% probability), and a bear case of $160-$175 (20% probability). The base case assumes continued RRP growth and stable margins, while the bull case requires faster RRP adoption and favorable regulation. The bear case would occur if regulatory actions or competition hurt growth. The most likely scenario is the base case, with the stock trading near the analyst average target of $203.80.
PM is fairly valued to slightly undervalued based on its PEG ratio of 0.36, which is well below the threshold of 1. The trailing PE of 22.06x is at a premium to the market average, but this is justified by the company's strong growth and high margins. The forward PE of 20.81x suggests the market expects earnings growth of ~6%, which is conservative given the RRP momentum. Compared to peers, PM trades at a similar multiple but with better growth prospects. Overall, the valuation is reasonable, and the stock is not overvalued.
PM is a good buy for investors seeking a defensive stock with growth potential. The analyst consensus is 'Buy' with an average target of $203.80, implying a 6.8% upside from the current price of $190.82. The stock offers a 3.46% dividend yield and a PEG ratio of 0.36, indicating it is undervalued relative to its growth rate. However, the main risk is regulatory actions that could impact RRP sales. For long-term investors with a 3-5 year horizon, PM is a solid addition, but for short-term traders, the stock may be near its fair value.
PM is more suitable for long-term investment due to its defensive nature and growth potential. The stock has a beta of 0.405, indicating low volatility, and offers a 3.46% dividend yield, making it attractive for income investors. The company's transition to RRPs is a multi-year story, and investors should hold for at least 3-5 years to fully benefit from the growth. Short-term trading may be less rewarding as the stock is near its 52-week high, but long-term investors can benefit from dividend growth and capital appreciation.